Illustration: Over-inflated translucent lungs over a brass oxygen valve turned partway open, copper haze trapped in the lower lobes.
← EMA Cited
EMA Cited · Pulmonary

COPD exacerbation

Updated Oct 22, 2026Adults · ED management9 sources · 7 checked in PubMed1 figureGOLD 2026

Bottom line

  • Titrate oxygen; don't flood it. Prehospital oxygen titrated to a saturation of 88–92% cut mortality compared with high-flow oxygen (4% vs 9%; RR 0.42).2
  • Short-acting bronchodilators first, a beta-agonist with or without a short-acting anticholinergic. Drive nebulizers with air rather than oxygen.1
  • Prednisone 40 mg daily for 5 days. In REDUCE, 5 days was noninferior to 14 days and halved the steroid dose. Oral works as well as IV.1,3
  • Antibiotics for purulent sputum, a prior positive sputum culture, or any ventilation. Give 5 days.1
  • NIV for respiratory acidosis (PaCO2 ≥ 45 mm Hg and pH ≤ 7.35). It cuts mortality (RR 0.54) and intubation (RR 0.36).1,4

Recognize and grade

An exacerbation is worsening dyspnea and/or cough and sputum over up to 14 days, sometimes with tachypnea or tachycardia. Most are triggered by viral infection; bacteria and air pollution also contribute.1 Pneumonia, pulmonary embolism, acute heart failure, arrhythmia, myocardial infarction and pneumothorax can mimic or worsen one.1

Rome severityFindings
MildDyspnea VAS < 5, RR < 24, HR < 95, resting SaO2 ≥ 92% (and a fall of ≤ 3% if baseline is known), CRP < 10 mg/L
Moderate (at least 3 of 5)Dyspnea VAS ≥ 5, RR ≥ 24, HR ≥ 95, SaO2 < 92% or a fall of > 3%, CRP ≥ 10 mg/L. A gas, if done, may show PaO2 70–80 mm Hg
SevereAs for moderate, plus a gas showing PaO2 ≤ 60 mm Hg and/or PaCO2 > 45 mm Hg with pH < 7.35

From GOLD 2026, which uses the Rome proposal. Dyspnea VAS runs 0–10. SaO2 is on room air or the patient's usual oxygen.1 Pulse oximetry is less accurate in people with darker skin.1

First hour

  1. Hypoxemic? Start controlled oxygen, aiming for a saturation of 88–92%.1,2
  2. Get a blood gas to decide on ventilatory support. A venous gas can help in less severe cases; arterial gas remains the standard in severe ones.1
  3. Bronchodilate: short-acting beta-agonist with or without ipratropium, by inhaler and spacer or air-driven nebulizer.1
  4. Give prednisone 40 mg (or equivalent) for moderate or severe exacerbations.1
  5. Decide on antibiotics using the criteria below.1
  6. Look for a mimic or complication: chest radiograph, and consider heart failure, arrhythmia, pulmonary embolism and pneumonia.1
  7. Acidosis or tiring? Start NIV (criteria below) or high-flow nasal oxygen, and arrange a monitored bed.1

Drugs

DrugAdult doseNotes
Ipratropium–albuterol nebulizedOne 3 mL vial (0.5 mg ipratropium + 2.5 mg albuterol base)GOLD: one nebulized dose every hour for 2–3 doses, then every 2–4 h by response. Avoid high SABA doses.1,9
Prednisone (or equivalent)40 mg PO daily5 days. Oral is as effective as IV.1,3
Antibiotic, when indicatedPer label and local resistanceUsually amoxicillin–clavulanate, a macrolide or a tetracycline; a quinolone in selected patients. 5 days.1
IV aminophylline or theophyllineNot recommendedSignificant side effects.1

Unreviewed doses. Verify against the current label and your institution's protocol before giving anything.

The ipratropium–albuterol label, written for maintenance, allows one vial four times a day plus two extra doses.9 The more frequent acute schedule is from GOLD.1 Continue or start long-acting bronchodilators before discharge.1

FIG 1The first week. Drawn for this page from GOLD 2026 and REDUCE. Steroids and antibiotics run 5 days. Symptoms usually last 7–10 days, and up to 20% of patients have not recovered by 8 weeks.1,3

Steroids

  • REDUCE (n = 314 ED patients, 92% admitted): prednisone 40 mg for 5 vs 14 days. Re-exacerbation within 180 days was 37.2% vs 38.4%, meeting noninferiority. The cumulative dose was 379 vs 793 mg.3
  • Even short steroid bursts are linked to later pneumonia, sepsis and death, so keep them for significant exacerbations.1 GOLD notes that low blood eosinophils may identify patients who can skip steroids, but hospital data are lacking.1

Antibiotics

  • GOLD gives antibiotics for: at least two of more dyspnea, fever, more sputum or purulent sputum, as long as purulence is one of them; a positive sputum culture in a prior exacerbation; or need for invasive or noninvasive ventilation.1
  • Send sputum cultures in frequent exacerbators, severe airflow obstruction or ventilated patients, who may carry Pseudomonas or resistant organisms.1
  • CRP can safely cut prescribing. In PACE (n = 653, UK primary care), CRP-guided care lowered antibiotic use (57.0% vs 77.4%) with no worse COPD health status at 2 weeks.6 GOLD does not recommend procalcitonin-guided protocols.1
Evidence is mixed

GOLD recommends antibiotics by the criteria above.1 The Cochrane review found clear benefit only in ICU patients (treatment failure RR 0.19, and lower mortality). For ward inpatients with currently used antibiotics, the reduction in treatment failure was not significant (RR 0.65, 95% CI 0.38–1.12). Outpatients had a small benefit on low-quality evidence (RR 0.72).5

Oxygen and ventilation

Start NIV if at least one of:
Respiratory acidosis: PaCO2 ≥ 45 mm Hg (6.0 kPa) and arterial pH ≤ 7.35
Severe dyspnea with signs of muscle fatigue or high work of breathing: accessory muscle use, paradoxical abdominal motion, intercostal retraction
Persistent hypoxemia despite supplemental oxygen

GOLD 2026 Figure 4.8.1 The ERS/ATS guideline makes a strong recommendation for NIV in acute or acute-on-chronic respiratory failure.8

  • NIV works. Across 17 trials (n = 1,264) of hypercapnic respiratory failure, NIV cut mortality (RR 0.54, NNT 12) and intubation (RR 0.36, NNT 5). Benefit was similar for pH 7.30–7.35 and pH < 7.30.4 GOLD reports NIV success rates of 80–85%.1
  • Titrated oxygen: in the Tasmanian prehospital trial (n = 405), titrating to 88–92% lowered mortality (4% vs 9%). In patients with confirmed COPD it was 2% vs 9%, with less acidosis and hypercapnia.2
  • High-flow nasal oxygen is GOLD's first choice for hypoxemic respiratory failure. For hypercapnic failure, or if high-flow fails, use NIV unless contraindicated.1
  • Intubate for life-threatening hypoxemia despite high-flow or NIV, intolerance of both, arrest, falling consciousness or uncontrolled agitation, massive aspiration or vomiting, inability to clear secretions, refractory shock, or severe arrhythmias.1
High-flow or NIV in hypercapnia?

Trials of high-flow nasal oxygen against NIV for hypercapnic exacerbations are mixed. In one, about 30% of patients on high-flow switched to NIV by 6 hours; others found it noninferior for intubation or death at 7 days. ERS guidelines still prefer NIV in hypercapnic respiratory failure.1

Disposition

SettingWho
HomeMild exacerbation, few comorbidities, cooperative, good home support1
AdmitSigns of respiratory failure (rising RR, accessory muscles, worsening hypoxemia or hypercapnia, altered mental status); no response to initial treatment; serious comorbidities such as heart failure or arrhythmia; poor home support1
ICU or respiratory unitPersistent or worsening hypoxemia or hypercapnia despite ventilatory support, worsening mental status, need for intubation, hemodynamic instability1
  • The Ottawa COPD Risk Scale was validated in 1,415 ED patients; 9.5% had a serious outcome within 30 days. A threshold above 1 raised sensitivity from 51.9% (current practice) to 79.3%, with admissions rising from 45.0% to 56.6%.7 GOLD does not recommend routine use of exacerbation scores.1
  • Before discharge: start or continue long-acting bronchodilators, check inhaler technique, and arrange follow-up within 1 month. Readmission within 30 days occurs in 30–50% of hospitalized patients.1
  • Prevent the next one: smoking cessation, vaccination (influenza, pneumococcal, RSV) and pulmonary rehabilitation.1 ERS/ATS suggests starting rehabilitation within 3 weeks of discharge, not during the admission.8
  • Admitted patients need thromboprophylaxis; up to 5.9% had a pulmonary embolism.1

Pitfalls

  • High-flow oxygen by default. Titrate to 88–92%.2
  • Oxygen-driven nebulizers in a hypercapnic patient. Use air.1
  • Steroids for 14 days when 5 is enough.3
  • Missing the mimic: pneumonia, pulmonary embolism, heart failure or pneumothorax.1
  • Delaying NIV in respiratory acidosis. Benefit holds even for mild acidosis (pH 7.30–7.35).4
  • Withholding ICU care from pessimism. Patients with COPD who are ventilated have lower acute mortality than those ventilated for other causes.1

How strong is the evidence?

GOLD grades short-acting bronchodilators as Evidence C, and steroids, antibiotic indications and NIV as Evidence A.1 NIV has the strongest support, with moderate-quality evidence on mortality and intubation.4 The oxygen-titration trial was a single prehospital cluster trial.2 Antibiotic benefit outside the ICU is small and inconsistent.5

On-shift teaching

Questions to ask a learner at the bedside. Tap a question to see the answer. Every answer uses facts cited above.

Q1What saturation target did the Tasmanian prehospital trial use, and what happened to mortality?
88–92%. Mortality was 4% vs 9% with high-flow oxygen (RR 0.42), and 2% vs 9% in confirmed COPD.2
Q2How long should prednisone run, and what is the evidence?
40 mg for 5 days. In REDUCE, 5 days was noninferior to 14 for re-exacerbation within 180 days (37.2% vs 38.4%) and halved the steroid dose.1,3
Q3When does GOLD recommend antibiotics?
At least two of more dyspnea, fever, more sputum or purulent sputum, with purulence one of them; a positive sputum culture in a prior exacerbation; or any mechanical ventilation. Give 5 days.1
Q4What are GOLD's indications for NIV?
Any one of: PaCO2 ≥ 45 mm Hg with pH ≤ 7.35; severe dyspnea with signs of muscle fatigue; or persistent hypoxemia despite oxygen.1
Q5How much does NIV help in hypercapnic exacerbations?
Mortality RR 0.54 (NNT 12) and intubation RR 0.36 (NNT 5), with similar benefit for pH 7.30–7.35 and below 7.30.4
Q6Why drive nebulizers with air instead of oxygen?
Oxygen-driven nebulization risks raising PaCO2 in an exacerbation.1

References

Evidence base

What this page is built on

9 sources, cited 66 times. Dots are sources, filled by how far each was read; stronger color means a larger share of the citations. Tap a tier to see its sources.

Read in full · 3Abstract read · 5Record only · 1Link checked · 0

Checked by the writer, not a physician. The dots show how each source was read, not that anyone has confirmed the claims.

How this page was made
  • Written from scratch. No source text was copied; facts are restated and cited.
  • Recommendations come from the full GOLD 2026 report (version 1.3), chapter 4, including its figures on place of care, management, NIV and intubation. GOLD 2026 does not state a numeric oxygen saturation target; the 88–92% target comes from the Austin trial's full text.
  • The ERS/ATS 2017 guideline is cited only for recommendations stated in its PubMed abstract.
  • Trial and review results were checked against their PubMed abstracts. Doses come from GOLD (prednisone, nebulizer frequency) and the FDA label (ipratropium–albuterol). No antibiotic doses are given.
  • No Tier A or B FOAM page on COPD exacerbation could be found or reached, so none is cited. Figure 1 was drawn for this page; no openly licensed image was used.
  • Adults only.
  • Not for clinical use.
Not for clinical use

AI-generated draft. Not reviewed by a physician. This page is for education only and may contain errors, including in doses. Do not use it to diagnose, treat or make decisions about any patient. Rely on your own clinical judgment, your institution's protocols and current drug labeling. Reading this page does not create a physician-patient relationship. Full terms